JPMorgan Chase & Co. grew its holdings in Codexis, Inc. (NASDAQ:CDXS - Free Report) by 484.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 183,906 shares of the biotechnology company's stock after acquiring an additional 152,438 shares during the period. JPMorgan Chase & Co. owned 0.23% of Codexis worth $877,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also modified their holdings of CDXS. State Street Corp raised its holdings in Codexis by 2.7% in the 3rd quarter. State Street Corp now owns 1,551,411 shares of the biotechnology company's stock worth $4,778,000 after purchasing an additional 41,480 shares during the period. Barclays PLC raised its stake in shares of Codexis by 51.1% in the third quarter. Barclays PLC now owns 207,628 shares of the biotechnology company's stock worth $640,000 after buying an additional 70,255 shares during the period. Geode Capital Management LLC lifted its position in shares of Codexis by 0.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,644,039 shares of the biotechnology company's stock valued at $5,065,000 after buying an additional 11,082 shares in the last quarter. Tallon Kerry Patrick bought a new position in shares of Codexis during the 4th quarter valued at approximately $2,018,000. Finally, Jackson Square Capital LLC bought a new position in shares of Codexis during the 4th quarter valued at approximately $210,000. Hedge funds and other institutional investors own 78.54% of the company's stock.
Codexis Stock Performance
NASDAQ CDXS traded up $0.20 on Friday, reaching $2.52. 591,184 shares of the stock were exchanged, compared to its average volume of 656,174. The company has a current ratio of 3.21, a quick ratio of 3.15 and a debt-to-equity ratio of 0.39. Codexis, Inc. has a one year low of $1.90 and a one year high of $6.08. The firm has a market capitalization of $208.75 million, a PE ratio of -2.90 and a beta of 2.35. The company's 50-day simple moving average is $2.55 and its two-hundred day simple moving average is $3.79.
Codexis (NASDAQ:CDXS - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.09). The firm had revenue of $21.46 million for the quarter, compared to the consensus estimate of $27.41 million. Codexis had a negative net margin of 96.35% and a negative return on equity of 71.56%. Analysts expect that Codexis, Inc. will post -0.77 EPS for the current fiscal year.
About Codexis
(
Free Report)
Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.
Further Reading
Before you consider Codexis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Codexis wasn't on the list.
While Codexis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
